Tag: chronic pain

Medtronic announces trial data on closed-loop and DTM SCS therapies at...

At this year’s North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas, USA), Medtronic announced new data from two clinical trials demonstrating...

Former Stimwave CEO hit with fraud charges over ‘fake, non-functional’ device...

The US Securities and Exchange Commission (SEC) has today charged Laura Tyler Perryman—the former chief executive officer (CEO) and co-founder of Florida-based medical device...

Biotronik announces new data supporting effectiveness of RESONANCE multiphase stimulation paradigm

Biotronik Neuro has announced that results from the BENEFIT-02 trial—the “first of its kind” to clinically evaluate a multiphase stimulation paradigm—support the effectiveness of...

SynerFuse announces presentation of IDE proof-of-concept study data

SynerFuse has announced that Michael Park (University of Minnesota, Minneapolis, USA)—principal investigator for the company’s investigational device exemption (IDE) proof-of-concept study—presented data from the study’s...

New study shows benefits of BioWave’s peripheral nerve stimulation in chronic...

The peer-reviewed journal Pain and Therapy recently published a new study, titled "Reduced pain and improved function following short-term use of non-invasive BioWave high-frequency peripheral...

Clinical trial to test novel wearable treatment for chronic pain and...

A multi-year clinical trial at the University of Texas Medical Branch (UTMB; Galveston, USA) and Medical University of South Carolina (MUSC; Charleston, USA) will...

Intermittent stimulation of the DRG produces comparable chronic pain results to...

Intermittent dorsal root ganglion stimulation (DRG-S) has been shown to produce comparable results to continuous stimulation across a two-week period, as reported in Neuromodulation:...

Nevro announces US FDA approval of HFX iQ system to personalise...

Nevro Corporation has announced that it has received approval from the US Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS)...

Stimwave announces sale of business and secures US$40 million in financing

Stimwave Technologies Incorporated (Stimwave) recently announced that it has reached an agreement to sell substantially all of its assets to Kennedy Lewis Management LP...

Medtronic announces first implant in study evaluating investigational, closed-loop neurostimulator

Medtronic today announced the first patient implant in a clinical study of its investigative, closed-loop, implantable neurostimulator. The ‘Evaluation of long-term patient experience with...

Abbott upgrades NeuroSphere myPath app for patient monitoring in neuromodulation trials

Abbott today announced that it has launched an upgraded version of its NeuroSphere myPath digital health app with enhanced functionality intended to help doctors...

Survey uncovers “far-reaching” impact of pandemic on patients with chronic back...

A new survey commissioned by Medtronic and conducted by public opinion research firm The Harris Poll has found that 44% of current chronic back...

Stimwave Technologies provides update on reimbursement of chronic pain therapies

Stimwave Technologies has provided an update on recent reimbursement-related progress pertaining to its chronic pain therapies—which include implantable spinal cord stimulation (SCS) and peripheral...

Multiple-modality spinal cord stimulation demonstrates sustained improvement in chronic pain outcomes

A spinal cord stimulation (SCS) system capable of simultaneously delivering multiple treatment modalities has produced a sustained improvement in outcomes in a randomised controlled...

Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...

Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...

Medtronic announces results showing meaningful pain relief using DTM SCS endurance...

Medtronic has announced three-month results from an on-label, prospective, multicentre study showing meaningful pain relief using DTM SCS endurance therapy—a modified, lower-energy variation of the...

Abbott announces expanded MRI compatibility for Proclaim XR spinal cord stimulation...

Abbott has announced that the US Food and Drug Administration (FDA) has approved new, expanded magnetic resonance imaging (MRI) compatibility for its Proclaim XR spinal cord...
spinal cord stimulation patient access

Current gaps and barriers in patient access to spinal cord stimulation

Maricela Schnur (St Luke’s Hospital, Duluth, USA) highlights a handful of socioeconomic disparities, racial differences, and psychological and psychiatric factors, that currently present difficulties...

FluxWear to debut wearable neuromodulation device at 2022 Consumer Electronics Show

FluxWear has announced that it will be demonstrating its first product at the Consumer Electronics Show (CES) early next year (5–8 January 2022, Las...

New protocol may reduce need for psychological assessments prior to neuromodulation...

Researchers at Toronto Western Hospital in Canada have proposed a protocol that may precede in-person assessments prior to patients receiving neuromodulation therapies. Their protocol...

SPR Therapeutics announces expanded FDA clearance for SPRINT peripheral nerve stimulation...

SPR Therapeutics has obtained clearance from the US Food and Drug Administration (FDA) of a broader indication for the usage of its SPRINT peripheral...
scs diabetic neuropathy

High-frequency SCS takes the stage to relieve chronic pain from diabetic...

Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...

Nevro announces FDA approval of 10kHz high-frequency SCS therapy for painful...

Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system for the treatment of chronic pain associated with...
neuros quest study

Neuros Medical gains FDA Breakthrough Device designation for Altius nerve block...

Neuros Medical has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for the use of its novel, high-frequency nerve block...
next-generation dbs devices

New algorithm could enable next-generation deep brain stimulation devices

By delivering small electrical pulses directly to the brain, deep brain stimulation (DBS) can ease tremors associated with Parkinson's disease or help relieve chronic...
spinal cord stimulation chronic pain

Study shows “major energy savings” can be achieved in spinal cord...

The results of the HALO (High and low frequency options) study, which are published online in the scientific journal Neuromodulation: Technology at the Neural...
blood test abbott

FDA approves Abbott’s iOS-compatible app for the management of chronic pain...

Abbott announces it has received approval from the US Food and Drug Administration (FDA) for the use of its Patient Controller app on compatible...
Medtronic logo

Medtronic launches Efficio software to help clinicians efficiently manage targeted drug...

Medtronic announce the launch of Efficio, a cloud-based data management software for use with the SynchroMed II intrathecal drug delivery system, that will allow...
proclaim abbott

FDA approves low-dose spinal cord stimulator for chronic pain

Abbott has received FDA approval for its Proclaim XR recharge-free neurostimulation system for people with chronic pain. A press release reports that the Proclaim...

Stimwave launches post-market peripheral neuropathy pain relief randomised controlled trial

In honour of September Pain Awareness Month, Stimwave has announced the launch of a new randomised clinical trial treating painful peripheral neuropathy, known as...

Nevro announces completion of patient enrolment in multicentre RCT of high...

Nevro has announced that it has completed patient enrolment in its prospective, multicentre randomised controlled trial (RCT) for the treatment of chronic pain for...

Similar success rates for anatomic and targeted lead placement for spinal...

“Anatomical lead placement is a viable alternative to targeted lead placement for spinal cord stimulation,” concluded Jason E Pope, Evolve Restorative Center, Santa Rosa,...

The first wireless spinal cord stimulator system elicits a high response...

A study evaluating different waveforms within a wireless spinal cord stimulator (SCS) device (Stimwave) has found high response rates for patients receiving both high...

Stimwave announces completion of enrolment for the Tsunami placebo-controlled double-blind randomised...

Stimwave has announced completion of patient enrolment and preliminary results of the first-of-its-kind Tsunami study. The Tsunami placebo-controlled double-blind randomised clinical trial (RCT) is...

Latest FDA caution for the use of off-label drugs in intrathecal...

While the US Food and Drug Administration (FDA) has called for caution regarding the use of off-label medications administered intrathecally, pain management experts have...

“Pain insensitive patient” may pave the way for new treatments of...

A recent study investigating a rare genetic mutation in a patient who “feels no pain” has suggested new routes to developing gene-therapy based analgesics...

Key findings from a review of the indications, complications, and incidence...

A retrospective database review of 12,297 spinal cord stimulator (SCS) patients outlines key findings concerning the indications, incidence of minor and major complications, and...

Burst stimulation of the spinal cord leads to greater pain modulation...

Data from a substudy of SUNBURST suggest that burst stimulation of the spinal cord regulates the medial pain pathway to a greater extent than...
Medtronic logo

Medtronic’s Evolve workflow with spinal cord stimulation demonstrates effective pain relief...

Medtronic has announced primary endpoint (three-month) results of the Vectors post-market clinical study that demonstrated effective pain relief and improved function in patients with...

International Neuromodulation Society announces 14th World Congress

The International Neuromodulation Society (INS) will hold its 14th World Congress from May 25–30, 2019 in Sydney, Australia. The multidisciplinary meeting highlights top international...

Stimwave announces publication of 10 kHz Freedom Stimulator SURF RCT results

Stimwave has announced publication of the results of the first ever randomised, controlled trial (RCT) comparing wireless high-frequency (HF: 10 kHz) spinal cord stimulation...
Medtronic logo

Medtronic announces FDA clearance and US launch of the Accurian RF...

Medtronic has announced US Food and Drug Administration (FDA) 510(k) clearance of the Accurian RF ablation platform, which conducts radio frequency (RF) ablation of...

Real-world review reports significant reduction in pain with high-frequency 10kHz SCS

A multicentre real-world review of 10kHz of spinal cord stimulation (SCS) for the treatment of chronic back and leg pain has elicited positive results,...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Study finds significant reduction in pain with high-frequency 10kHz peripheral nerve...

A randomised controlled trial (RCT) of peripheral nerve stimulation (PNS) at 10kHz frequency demonstrates a significant reduction in pain scores for patients suffering from...

Nuvectra receives full-body MR-conditional CE Mark approval for Algovita

Nuvectra has announced that it has received full-body MR-conditional approval for the Company’s Algovita spinal cord stimulation (SCS) system from its European Notified Body,...

New approvals allow chronic pain sufferers to try Abbott’s non-opioid pain...

Abbott has announced the launch of the new dorsal root ganglion (DRG) Invisible Trial System, which is approved by the US Food and Drug...

First use of SPRINT endura peripheral nerve stimulation system to treat...

SPR Therapeutics has announced that Marc Huntoon, director of pain management at the Neuroscience, Orthopaedic and Wellness Center, VCU Medical Center, was the first...

Stimwave receives FDA clearance for first Wireless SCS System with iPhone-iWatch...

Stimwave Technologies has announced that it has received US Food and Drug Administration (FDA) clearance for the WaveCrest Mobile iOS platform patient controllers for...

FDA approves new SynchroMed II myPTM Personal Therapy Manager that enables...

Medtronic has announced US Food and Drug Administration (FDA) approval of the new SynchroMed II myPTM Personal Therapy Manager for patients with chronic pain....

Spinal cord stimulation and chronic pain: In the end it’s about...

Krishnan Chakravarthy writes in NeuroNews about how spinal cord stimulation can be used to treat chronic pain and how this can help America overcome...

Neurostimulation can be part of the solution to the opioid crisis

The president of the United States of America has recently declared the opioid crisis in that country a “public health emergency”. In light of...

Innovation. Outcomes. Focus on Function.

Medtronic has a long-standing commitment to delivering innovative pain stimulation technology and building the evidence that matters today and leads us into the future. This is again...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

WHISPER SCS study: therapy optimisation associated with more effective pain relief

New data from the WHISPER randomised controlled trial (RCT) have demonstrated that patients who are given the choice to use both sub-perception and paraesthesia-based...

Spectra WaveWriter Spinal Cord Stimulator System receives FDA approval

The Spectra WaveWriter Spinal Cord Stimulator (SCS) System (Boston Scientific) has received FDA approval. It is the first and only system approved by the...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

FDA approves Senza II Spinal Cord Stimulation System

The US Food and Drug Administration has approved the next-generation Senza II Spinal Cord Stimulation (SCS) System (Nevro) delivering HF10 therapy. According to the company,...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

FDA approves new clinician programmer for SynchroMed II intrathecal drug delivery...

The US Food and Drug Administration (FDA) has approved a new clinician programmer for use with the SynchroMed II Intrathecal Drug Delivery system (Medtronic),...

First patient enrolled in study to assess optimised spinal cord stimulation...

The first patient has been enrolled in the Vectors Post Market Clinical Study. The study will follow patients with chronic intractable pain who are...

StimRouter Neuromodulation System eligible for increased Medicare reimbursements

  The Centers for Medicare & Medicaid Service (CMS) has approved significantly larger payment rates for the StimRouter Neuromodulation System (Bioness) in the Hospital Outpatient...

Radiofrequency treatment provides pain relief in new study

A study presented at the annual meeting of the Radiological Society of North America (RSNA, 26 November-1 December, Chicago, USA) has found that the...

NANS responds to California DWC order to discontinue coverage of non-opioid...

The North American Neuromodulation Society (NANS) has issued a response to the California Division of Workers’ Compensation (DWC) order which adopts regulations to update the evidence-based...

Nevro receives CE mark for full-body MRI conditional labelling with the...

Nevro has received the CE mark for full-body magnetic resonance imaging (MRI) conditional labelling on the Senza Spinal Cord Stimulation (SCS) System delivering HF10...

Intellis platform receives CE mark for spinal cord and peripheral nerve...

Medtronic has received CE mark for the Intellis platform for both spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) as an aid in...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Closed-loop spinal cord stimulation may represent new paradigm to mitigate tolerance

With six-month follow-up indicating that dorsal column activation is regulated to therapeutic levels by closed-loop spinal cord stimulation (SCS) using evoked compound action potentials...

FDA approves Intellis platform for chronic pain

The US Food and Drug Administration has approved the Intellis spinal cord stimulation platform (Medtronic) for the management of certain types of chronic intractable...

Evidence in favour of DRG stimulation builds with real-world data

The real-world data collected in the PREDICT study has added to the evidence in favour of dorsal root ganglion (DRG) stimulation for the management...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

No difference in pain relief between 1kHz and 10kHz spinal cord...

A randomised controlled trial has found excellent pain relief and no clinical difference among spinal cord stimulation frequencies from 1kHz–10kHz. Further, the study showed...

US FDA clears Stimwave’s full-body MRI-ready wireless peripheral nerve stimulator

Stimwave has received US Food and Drug Administration (FDA) 510(k) clearance for the first wireless, micro-technology neuromodulation device that can enable ongoing full-body MRI...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

DBS for chronic neuropathic pain efficacious at three years’ follow-up

A study published in the journal Neuromodulation has shown efficacy at three years’ follow-up for deep brain stimulation (DBS) for the treatment of neuropathic...

FDA clears Stimpod NMS460 non-invasive neuromodulation device

The US Food and Drug Administration (FDA) has cleared the Stimpod NMS460 (Xavant Technology). With the US patent awarded on proprietary hybrid pulsed radio...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Marking 50 years of spinal cord stimulation

The year 2017 marks the 50th anniversary for spinal cord stimulation therapy which was first used to treat pain in 1967. To celebrate the...

Saluda Medical secures US$40 million in series D financing

Saluda Medical, a medical device company developing a platform of closed-loop neuromodulation technologies based on neural response to stimulation, has secured US$40 million in...

CE mark approval for Stimwave’s world-first fully percutaneous spinal cord stimulator...

CE mark approval has been granted for the world’s first percutaneous injectable anchor system, SandShark. The Stimwave system is used to fixate the company’s...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Higher trial-to-implant ratio found at high-volume SCS centres

A study carried out by Kelly Ryan Murphy (Duke University Medical Center, Durham, USA) and colleagues has found that centres with high-volume spinal cord...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Prospective study shows good efficacy with high-frequency spinal cord stimulation in...

A study published in the journal Neuromodulation reports good efficacy with high-frequency spinal cord stimulation with notable reductions on the numerical rating scale back...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Low-profile multicolumn paddle lead improves access to spinal canal

A low-profile multicolumn paddle lead has provided an option for spinal cord stimulation therapy in an area which traditionally is difficult to access with...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Individualised patient care the future of SCS

A multicentre, double-blind, randomised and placebo-controlled crossover trial has found that patients with complex regional pain syndrome (CRPS) show preference for different spinal cord...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

More research needed to show potential of neuromodulation

While much has been done in the past decade to advance the field of neuromodulation, some investigators believe only small steps have been made...
burst spinal cord stimulation TRIUMPH

Spinal cord stimulation reduces or stabilises opioid use among chronic pain...

New research has found spinal cord stimulation therapy can reduce or stabilise the use of opioids in patients battling chronic pain. Researchers examined opioid...

Proclaim DRG Neurostimulation System introduced in Europe

Abbott has announced the European launch of the new Proclaim DRG Neurostimulation System, designed to deliver dorsal root ganglion (DRG) stimulation to patients suffering...
patients suffering from complex regional pain syndrome

ACCURATE 12-month data published in Pain

New data published in the January edition of Pain has confirmed the superiority of dorsal root ganglion (DRG) stimulation therapy (from Abbott) over traditional...

Nuvectra picks up New Product Innovation Award for SCS device

Based on its recent analysis of the spinal cord stimulation (SCS) market, Frost & Sullivan has recognised Nuvectra with the 2017 North American New...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

New guidance on neuromodulation therapy to be published

The International Neuromodulation Society (INS) journal Neuromodulation: Technology at the Neural Interface is publishing expert, evidence-based guidance on the safe and efficient use of neuromodulation implants in patient-centred...

CE mark for full body MR conditional labelling for Proclaim Elite...

The Proclaim Elite spinal cord stimulation (SCS) system (St Jude Medical) has received CE mark approval for full-body magnetic resonance (MR) conditional labelling. With...

CE mark for Quell wearable pain relief device

NeuroMetrix has received CE mark for the Quell wearable pain relief device. This certification in the European Union allows sales and marketing of Quell...

Proclaim Elite spinal cord stimulation system earns full-body MRI compatibility labelling

The US Food and Drug Administration (FDA) has approved full-body magnetic resonance (MR) conditional labelling for the Proclaim Elite spinal cord stimulation (SCS) system (St Jude Medical)....
patients suffering from complex regional pain syndrome

Southeast Pain Care uses new Axium neurostimulator for chronic pain

Southeast Pain Care is one of the first facilities in North Carolina, USA, to use a new neurostimulation device designed to relieve the sensation...

FDA approves BurstDR stimulation for patients with chronic pain

The US Food and Drug Administration (FDA) has approved BurstDR stimulation, a physician-designed form of spinal cord stimulation (SCS) clinically proven to provide superior outcomes for...

Study urges earlier consideration of spinal cord stimulation in chronic pain...

A study recently published in the journal Neuromodulation suggests that earlier consideration of spinal cord stimulation in chronic pain care continuum could have a...

SCS TechTalk: Innovation Starts Here

In this Boston Scientific Educational Supplement, you will read about the pace of innovation—from delivering the first and only rechargeable spinal cord stimulation (SCS) system powered by intuitive...

Two year SENZA-RCT results demonstrate sustained superiority of high-frequency 10 therapy...

Two-year SENZA-RCT results have been published in Neurosurgery, according to Nevro.  The SENZA-RCT is a pivotal study that is both the largest prospective randomised...
burst spinal cord stimulation TRIUMPH

Most patients with chronic trunk or limb pain experience “substantial” pain...

Twenty-four month data from a postmarket, clinical registry have found that most patients suffering from chronic pain of the trunk and/or limbs reported “substantial”...

Nuvectra reports first quarter financial results

Nuvectra has announced the company’s financial results for the first quarter of 2016. According to a press release, total revenue in the first quarter of...
patients suffering from complex regional pain syndrome

First US commercial implants of Axium DRG system announced

St Jude Medical has announced the US launch and first post-approval implants of the St Jude Medical Axium Neurostimulator System for dorsal root ganglion (DRG) stimulation...

St. Jude Medical: Returning innovation to chronic pain treatment

With a series of acquisitions and recent product approvals, St. Jude Medical has further solidified its place as a leading provider of treatment options...

High-density stimulation restores efficacy in failed spinal cord stimulation therapy

By reprogramming existing spinal cord stimulation systems, investigators have been able to restore efficacy in patients who have failed spinal cord stimulation therapy, and...

SUNBURST data demonstrates superior pain relief results for Burst Stimulation over...

St Jude Medical’s Burst stimulation can relieve chronic pain more effectively than traditional tonic spinal cord stimulation (SCS), according to the SUNBURST study. The...

St Jude Medical launches spinal cord stimulation system in Europe

St Jude Medical has launched its Proclaim Elite spinal cord stimulation (SCS) system in Europe. According to a press release, this is the world’s...

FDA approves Proclaim Elite SCS System

St Jude Medical has announced FDA approval of the new Proclaim Elite Spinal Cord Stimulation System, the first and only upgradeable and recharge-free spinal cord stimulation (SCS)...

St Jude Medical receives CE mark for MRI conditional labelling of...

St Jude Medical has received CE mark approval for magnetic resonance imaging (MRI) conditional labelling for the company’s Prodigy MRI chronic pain system with...